TaperCommunity
Mirtazapine, sold under the brand name Remeron, is a tetracyclic antidepressant prescribed for depression, insomnia, anxiety, and appetite stimulation. Like other antidepressants, stopping it can produce a distinct cluster of physical and psychological effects known as discontinuation syndrome. Mirtazapine withdrawal symptoms are common, often underestimated by prescribers, and can be intense even after short-term use. This guide explains what symptoms tend to appear, why they happen, how long they typically last, and what evidence-based tapering looks like. The goal is to give you accurate information so you can have a more productive conversation with your prescriber and make informed choices about how to come off this medication safely.
Mirtazapine works differently from SSRIs or SNRIs. It blocks alpha-2 adrenergic autoreceptors, which increases the release of norepinephrine and serotonin. It also strongly antagonizes histamine H1 receptors, which is why it causes sedation and weight gain, particularly at lower doses. At higher doses, the noradrenergic effects start to dominate, which is why some people find 7.5mg more sedating than 30mg.
The brain adapts to this constant signaling over weeks and months. Receptor density shifts. Downstream pathways recalibrate. When the drug is removed, those adaptations remain in place for a period of time, and the nervous system has to relearn how to regulate sleep, mood, anxiety, and appetite without the medication. This is the biological basis for discontinuation syndrome.
This is not the same as addiction. There is no craving, no compulsive drug-seeking, no escalating dose to chase a high. It is a physiological dependence that develops in nearly everyone who takes the medication consistently. Understanding this distinction matters because dependence is medically expected and not a sign of personal weakness or relapse.
The Royal College of Psychiatrists updated its guidance in 2019 to acknowledge that antidepressant withdrawal can be severe and prolonged in a significant minority of patients. Mirtazapine is included in that category despite a popular myth that it is somehow easier to stop than SSRIs.
The most frequently reported mirtazapine withdrawal symptoms cluster into several categories. Sleep disturbance is almost universal. Because mirtazapine is a powerful sedative through H1 antagonism, removing it can trigger severe rebound insomnia, vivid dreams, nightmares, and fragmented sleep. People who took it primarily for sleep often find this the most distressing part of stopping.
Anxiety, agitation, and irritability are also extremely common. The norepinephrine system, which has been dampened by alpha-2 blockade, surges as the drug clears. This can produce a wired, restless feeling, racing thoughts, panic, and a short fuse. Some people describe it as feeling electrified or unable to settle.
Gastrointestinal symptoms appear often: nausea, loss of appetite (the opposite of mirtazapine's usual effect), diarrhea, and stomach pain. Flu-like symptoms including headaches, sweating, chills, and muscle aches are reported by many. Dizziness and balance problems can occur, though they are less prominent than with SSRIs like paroxetine.
Cognitive symptoms include brain fog, difficulty concentrating, and a general sense of unreality or depersonalization. Mood symptoms include depression, tearfulness, and emotional volatility that can be mistaken for relapse but often resolves once the nervous system stabilizes. Sensory symptoms such as itching, tingling, and skin sensitivity also appear in some users.
Duration varies widely and depends on dose, length of use, individual neurobiology, and tapering method. Acute symptoms typically begin within 24 to 72 hours of a dose reduction or stop, peak in the first week or two, and gradually subside over four to six weeks for most people who tapered carefully.
A subset of people experience protracted withdrawal, where symptoms persist for months or even longer. This is more likely after long-term use or after a rapid taper. Horowitz and Taylor, in their 2019 Lancet Psychiatry paper, documented that antidepressant withdrawal is more common, more severe, and longer-lasting than guidelines had previously suggested. Their work has since informed the Maudsley Deprescribing Guidelines, which now recommend hyperbolic tapering for all antidepressants including mirtazapine.
People who stopped abruptly or used standard linear tapers tend to report longer and more intense symptoms than those who reduced more gradually using smaller proportional decrements. Sleep disturbance is often the last symptom to resolve, sometimes lingering for several months as the histaminergic system recalibrates.
The phrase "it will pass in two weeks" comes from older clinical guidance that does not reflect what many patients actually experience. Plan for a longer arc, hope for a shorter one.
The intensity of mirtazapine withdrawal symptoms surprises many people because the drug is sometimes marketed as gentle or easy to come off. Several factors explain the gap between expectation and reality.
First, mirtazapine acts on multiple receptor systems simultaneously: histamine, serotonin, norepinephrine, and several serotonin subtype receptors. Stopping it means the brain has to readjust across all of those systems at once, which produces a broader symptom profile than drugs with narrower targets.
Second, the elimination half-life of mirtazapine is around 20 to 40 hours. This is shorter than fluoxetine but longer than venlafaxine. The relatively quick clearance means receptor occupancy drops noticeably between doses once tapering begins, especially at the lower end of the dose range.
Third, the relationship between dose and receptor occupancy is not linear. It follows a hyperbolic curve. This means a reduction at higher doses produces a much smaller change in receptor binding than a similarly sized reduction at low doses. The final stages of tapering are where most of the receptor change happens, which is why many people struggle near the end despite being on what looks like a tiny dose. Read more on the Remeron drug profile for additional context.
Fourth, mirtazapine is often prescribed alongside SSRIs, SNRIs, or benzodiazepines. Coming off it while still on other psychoactive medications, or coming off all of them at once, multiplies the difficulty and confuses the symptom picture.
The principle behind safer tapering is hyperbolic reduction: each dose decrease should produce roughly the same proportional change in receptor occupancy as the last one. In practice, this means smaller and smaller absolute reductions as the dose gets lower.
Below the lowest available tablet strength, custom compounded liquid or carefully split tablets are often needed, because standard tablets do not allow fine enough adjustments. Some people use a compounding pharmacy; others use a tapering strip service where available.
The rate of reduction should be slow enough that symptoms remain tolerable. There is no universal correct speed. What matters is listening to your body and adjusting based on how you feel, not adhering rigidly to a calendar. Holding at a dose for a few extra weeks when symptoms flare is not failure. It is responsible tapering.
If you are reducing and sleep collapses for more than a week or two, that is a signal to slow down, not push through. The nervous system is telling you it needs more time. This is also where peer support becomes valuable, because experienced taperers in places like taper.community can share what worked for them at similar stages.
Avoid stopping mirtazapine abruptly unless a medical situation demands it. Cold turkey discontinuation is associated with the most severe and prolonged symptoms.
One of the hardest parts of stopping mirtazapine is figuring out whether returning symptoms are withdrawal or a return of the original condition. The distinction matters because the response is different.
Withdrawal symptoms usually appear within days of a dose reduction, include physical features that were not part of the original illness (nausea, flu-like feelings, brain zaps, sensory disturbances), and improve with time or with reinstating a small dose. Relapse, by contrast, tends to emerge weeks or months after stopping, mirrors the original symptom pattern without the physical features, and does not respond to reinstatement of the medication in the same rapid way.
Sleep is a tricky area because both insomnia and rebound insomnia can look similar. The clue is often timing: rebound insomnia is worst in the first weeks after a reduction and gradually improves, while relapse-related insomnia tends to build slowly over a longer period.
If you are uncertain, a small reinstatement for a few days can clarify the picture. If symptoms ease quickly, withdrawal is likely. If they do not, the original condition may be returning. The Maudsley Deprescribing Guidelines describe this approach in detail and consider it a legitimate diagnostic tool, not a sign of failure.
Most prescribers are willing to support a careful taper if you bring evidence and a clear plan. The Maudsley Deprescribing Guidelines, the Horowitz and Taylor 2019 Lancet Psychiatry paper, and the updated Royal College of Psychiatrists position statement are all reasonable references to share. Coming in informed changes the conversation.
Reach out for medical input if symptoms become severe, if you develop suicidal thoughts, if you cannot sleep at all for several nights, if you experience chest pain or seizures, or if you simply feel unable to manage the process alone. There is no prize for white-knuckling through an intolerable withdrawal.
A prescriber who insists that mirtazapine has no withdrawal syndrome, or who pushes a rapid two-week taper, may not be up to date with current evidence. You can ask for a second opinion or seek out a clinician familiar with deprescribing. Patient-led tapering communities have helped many people find prescribers who take the process seriously.
You can, but it is not recommended. Abrupt discontinuation tends to produce the most severe and longest-lasting withdrawal symptoms. A gradual taper is much more tolerable for the vast majority of users.
Many people find the final stretch the hardest part of tapering. This is because receptor occupancy changes more dramatically per milligram at low doses than at high ones, due to the hyperbolic dose-response curve.
Appetite usually decreases during withdrawal, sometimes dramatically, and weight loss is common in the first weeks. Whether long-term weight stays down depends on many factors beyond the medication.
Sleep hygiene becomes crucial: consistent wake times, no screens before bed, cool dark rooms, no caffeine after noon. Some people find melatonin, magnesium, or non-pharmacological approaches like CBT-I helpful. Avoid jumping to another sedating medication if possible, as it usually just shifts the problem.
Yes, in a minority of users. Protracted withdrawal lasting months or longer is documented in the literature and in patient reports. It is more likely after long-term use or rapid tapers, which is one of the strongest arguments for going slowly.
Mirtazapine withdrawal symptoms are real, common, and often more intense than older clinical guidance suggests. They are also manageable with a slow, hyperbolic taper and good support. If you are starting to think about coming off Remeron, take the time to plan, find a prescriber who understands deprescribing, and connect with others who have done it. You do not have to figure this out alone. The community at taper.community exists precisely for this kind of shared learning, and our forums on tapering and symptom management are open to anyone navigating this process.
Medical disclaimer: This article is for informational and educational purposes only and is not medical advice. Decisions about starting, stopping, or changing any medication should be made in consultation with a qualified healthcare provider who knows your individual history. Withdrawal experiences vary, and what works for one person may not be appropriate for another.